Ritholtz Wealth Management Has $7.24 Million Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Ritholtz Wealth Management lowered its stake in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 13.7% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 104,309 shares of the company's stock after selling 16,517 shares during the quarter. Ritholtz Wealth Management's holdings in Novo Nordisk A/S were worth $7,243,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Center for Financial Planning Inc. boosted its position in Novo Nordisk A/S by 72.4% during the fourth quarter. Center for Financial Planning Inc. now owns 293 shares of the company's stock worth $25,000 after purchasing an additional 123 shares during the period. Strategic Investment Solutions Inc. IL boosted its position in shares of Novo Nordisk A/S by 2,727.3% in the fourth quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock valued at $27,000 after acquiring an additional 300 shares during the period. Park Square Financial Group LLC bought a new stake in shares of Novo Nordisk A/S in the fourth quarter valued at approximately $29,000. Transce3nd LLC bought a new stake in shares of Novo Nordisk A/S in the fourth quarter valued at approximately $33,000. Finally, Kelly Lawrence W & Associates Inc. CA bought a new stake in shares of Novo Nordisk A/S in the fourth quarter valued at approximately $39,000. Institutional investors own 11.54% of the company's stock.

Novo Nordisk A/S Stock Performance

Shares of NYSE NVO traded down $1.15 during trading hours on Friday, reaching $79.90. The stock had a trading volume of 7,465,072 shares, compared to its average volume of 7,042,462. The business's fifty day moving average is $67.30 and its two-hundred day moving average is $79.63. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55. The company has a market cap of $358.57 billion, a price-to-earnings ratio of 24.29, a PEG ratio of 0.90 and a beta of 0.66. Novo Nordisk A/S has a twelve month low of $57.00 and a twelve month high of $148.15.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported $0.92 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.92. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. The firm had revenue of $11.87 billion during the quarter. As a group, research analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on NVO shares. Dbs Bank cut Novo Nordisk A/S to a "sell" rating in a research report on Friday, April 25th. BNP Paribas started coverage on Novo Nordisk A/S in a research report on Tuesday, April 15th. They issued an "underperform" rating for the company. Stifel Nicolaus cut Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research report on Monday, March 3rd. Guggenheim lowered Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research note on Thursday, April 17th. Finally, Hsbc Global Res upgraded Novo Nordisk A/S to a "strong-buy" rating in a research note on Monday, April 28th. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating, four have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, Novo Nordisk A/S currently has an average rating of "Hold" and an average price target of $112.00.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.